Herzfrequenz: klinische Variable und Risikomarker

F. Custodis; J.-C. Reil; S. H. Schirmer; O. Adam; S. Möhlenkamp; U. Laufs; M. Böhm

doi:10.1055/s-0034-1370223

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2014; 139(33): 1661-1672
DOI: 10.1055/s-0034-1370223

CME | Review article

Kardiologie

Herzfrequenz: klinische Variable und Risikomarker

Heart rate: clinical variable and risk marker

F. Custodis

¹Kardiologie, Angiologie u. Internistische Intensivmedizin, Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes

,

J.-C. Reil

¹Kardiologie, Angiologie u. Internistische Intensivmedizin, Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes

,

S. H. Schirmer

¹Kardiologie, Angiologie u. Internistische Intensivmedizin, Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes

,

O. Adam

¹Kardiologie, Angiologie u. Internistische Intensivmedizin, Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes

,

S. Möhlenkamp

²Abteilung f. Kardiologie, Internistische Intensivmedizin, Krankenhaus Bethanien, Moers

,

U. Laufs

¹Kardiologie, Angiologie u. Internistische Intensivmedizin, Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes

,

M. Böhm

¹Kardiologie, Angiologie u. Internistische Intensivmedizin, Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes

› Author Affiliations

Abstract

Zusammenfassung

Die Herzfrequenz ist eine einfache klinische Variable mit weitreichender prognostischer Bedeutung. Eine unter Ruhebedingungen erhöhte Herzfrequenz ist mit einem erhöhten kardiovaskulären Risiko verknüpft. Daten epidemiologischer Studien demonstrieren sowohl für Personen ohne bekannte kardiovaskuläre Erkrankungen sowie für Individuen mit bestehenden kardiovaskulären Erkrankungen wie arterieller Hypertonie, koronarer Herzerkrankung (KHK) und chronischer Herzinsuffizienz eine relevante Assoziation zwischen der Höhe der Herzfrequenz und der mittleren Überlebenszeit. Während eine gezielte medikamentöse Herzfrequenzreduktion im Rahmen der Primärprävention bislang keine Rolle spielt, ist sie bei Patienten mit KHK und chronischer Herzinsuffizienz von wesentlicher symptomatischer und prognostischer Bedeutung. Für die Herzinsuffizienz und möglicherweise auch die KHK ist die Herzfrequenz darüber hinaus als unabhängiger Risikofaktor anzusehen. Demnach weisen die Leitlinien eine Reduktion der Herzfrequenz als Therapieziel der medikamentösen Behandlung aus.

Abstract

Heart rate is an easily accessible clinical variable with wide-ranging prognostic impact. Elevated resting heart rate predicts an elevated cardiovascular risk. Epidemiological studies demonstrate a relevant association between heart rate and survival in individuals without diagnosed cardiovascular disease and with cardiovascular disease like hypertension, coronary artery disease (CAD) and heart failure. Whereas a goal directed pharmacological heart rate reduction is not supported by clinical evidence for primary prevention it plays a prognostic role for patients with CAD and chronic heart failure. Moreover heart rate can be characterized as an independent risk factor for patients with heart failure and potentially for those with CAD. As a result the common guidelines recommend heart rate reduction as a target of therapy.

Schlüsselwörter

Herzfrequenz - kardiovaskuläres Risiko - Risikomarker - Risikofaktor

Keywords

heart rate - cardiovascular risk - risk marker - risk factor

Full Text

References

Literatur
1 Abrahamsson P, Swedberg K, Borer JS et al. Risk following hospitalization in stable chronic systolic heart failure. Eur J Heart Fail 2013; 15: 885-891
2 Al Bannay R, Böhm M, Husain A. Heart rate differentiates urgency and emergency in hypertensive crisis. Clin Res Cardiol 2013; 102: 593-598
3 Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984; 226: 180-182
4 Benetos A, Rudnichi A, Thomas F et al. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension 1999; 33: 44-52
5 Böhm M. Pathophysiology of heart failure today. Herz 2002; 27: 75-91
6 Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102: 11-22
7 Böhm M, Cotton D, Foster L et al. Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. Eur Heart J 2012; 33: 2804-2812
8 Böhm M, Swedberg K, Komajda M et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376: 886-894
9 Böhm M, Thoenes M, Neuberger HR et al. Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients. Eur Heart J 2009; 30: 1364-1371
10 Bonaa KH, Arnesen E. Association between heart rate and atherogenic blood lipid fractions in a population. The Tromso Study. Circulation 1992; 86: 394-405
11 Borer JS, Böhm M, Ford I et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure with left ventricular dysfunction (from the SHIFT Trial). Am J Cardiol 2013; in press
12 Cooney MT, Vartiainen E, Laatikainen T et al. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J 2010; 159: 612-619 e613
13 Correale M, Montrone D, Biase MD et al. Safe and well-tolerated treatment with ivabradine in systemic sclerosis affected by pulmonary hypertension. Clin Res Cardiol 2012; 101: 593-594
14 Custodis F, Baumhäkel M, Schlimmer N et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008; 117: 2377-2387
15 Custodis F, Gertz K, Balkaya M et al. Heart rate contributes to the vascular effects of chronic mental stress: effects on endothelial function and ischemic brain injury in mice. Stroke 2011; 42: 1742-1749
16 Custodis F, Reil JC, Laufs U et al. Heart rate and rate control : Prognostic value in cardiovascular diseases. Der Internist 2012; 53: 6-13
17 Custodis F, Reil JC, Laufs U et al. Heart rate: a global target for cardiovascular disease and therapy along the cardiovascular disease continuum. Journal of cardiology 2013; 62: 183-187
18 Custodis F, Schirmer SH, Baumhäkel M et al. Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol 2010; 56: 1973-1983
19 Diaz A, Bourassa MG, Guertin MC et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-974
20 DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I-f current inhibition with ivabradine – A new therapeutic perspective in cardiovascular disease. Drugs 2004; 64: 1757-1765
21 Dyer AR, Persky V, Stamler J et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 1980; 112: 736-749
22 Ekman I, Chassany O, Komajda M et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 2011; 32: 2395-2404
23 Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012; 60: e44-e164
24 Flannery G, Gehrig-Mills R, Billah B et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008; 101: 865-869
25 Fox K, Borer JS, Camm AJ et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50: 823-830
26 Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807-816
27 Fox K, Ford I, Steg PG et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009; 30: 2337-2345
28 Franke J, Wolter JS, Meme L et al. Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed?. Clin Res Cardiol 2013; 102: 23-31
29 Gillman MW, Kannel WB, Belanger A et al. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993; 125: 1148-1154
30 Gillum RF. The epidemiology of resting heart rate in a national sample of men and women: associations with hypertension, coronary heart disease, blood pressure, and other cardiovascular risk factors. Am Heart J 1988; 116: 163-174
31 Grassi G, Vailati S, Bertinieri G et al. Heart rate as marker of sympathetic activity. J Hypertens 1998; 16: 1635-1639
32 Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-1482
33 Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol 2008; 153: 1589-1601
34 Hjalmarson A. The role of heart rate in cardiovascular disease. Dialogues in Cardiovascular Medicine 2010; 15: 179-191
35 Hjalmarson A, Gilpin EA, Kjekshus J et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990; 65: 547-553
36 Ho JE, Bittner V, Demicco DA et al. Usefulness of heart rate at rest as a predictor of mortality, hospitalization for heart failure, myocardial infarction, and stroke in patients with stable coronary heart disease (Data from the Treating to New Targets [TNT] trial). Am J Cardiol 2010; 105: 905-911
37 Hoke RS, Muller-Werdan U, Lautenschlager C et al. Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study. Clin Res Cardiol 2012; 101: 139-147
38 Jouven X, Empana JP, Schwartz PJ et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352: 1951-1958
39 Julius S. Tachycardia in hypertension: a saga of progress despite prejudice, confusion, and inertia. Prog Cardiovasc Dis 2009; 52: 26-30
40 Kannel WB, Kannel C, Paffenbarger Jr RS Jr et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1489-1494
41 Kaye DM, Lefkovits J, Jennings GL et al. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995; 26: 1257-1263
42 Kolloch R, Legler UF, Champion A et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008; 29: 1327-1334
43 Komajda M, Böhm M, Borer J et al. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure. Eur J Heart Fail 2013; 15: 79-84
44 Komajda M, Böhm M, Borer JS et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and low blood pressure in the SHIFT trial. Eur J Heart Fail 2013; 16: 810-816
45 Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol 1997; 30: 1104-1106
46 Levy RL, White PD, Stroud WD. Transient tachycardia: prognostic significance alone and in association with transient hypertension. JAMA 1945; 129: 585-588
47 Lonn EM, Rambihar S, Custodis F et al. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Clin Res Cardiol 2013; 103: 149-159
48 Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-2219
49 Marks RG, Hale WE, Moore MT et al. Resting heart rates in an ambulatory elderly population: an evaluation of age, sex, symptoms, and medication. Gerontology 1989; 35: 210-217
50 McAlister FA, Wiebe N, Ezekowitz JA et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784-794
51 McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847
52 Morcet JF, Safar M, Thomas F et al. Associations between heart rate and other risk factors in a large French population. J Hypertens 1999; 17: 1671-1676
53 Nanchen D, Leening MJ, Locatelli I et al. Resting heart rate and the risk of heart failure in healthy adults: the Rotterdam Study. Circulation Heart failure 2013; 6: 403-410
54 Nuding S, Ebelt H, Hoke RS et al. Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine : MODI (f)Y trial. Clin Res Cardiol 2011; 100: 915-923
55 Okin PM, Kjeldsen SE, Julius S et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J 2010; 31: 2271-2279
56 Palatini P. Elevated heart rate in cardiovascular diseases: a target for treatment?. Prog Cardiovasc Dis 2009; 52: 46-60
57 Palatini P, Benetos A, Grassi G et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006; 24: 603-610
58 Palatini P, Casiglia E, Pauletto P et al. Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations. Hypertension 1997; 30: 1267-1273
59 Palatini P, Thijs L, Staessen JA et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162: 2313-2321
60 Pfister R, Michels G, Sharp SJ et al. Resting heart rate and incident heart failure in apparently healthy men and women in the EPIC-Norfolk study. Eur J Heart Fail 2012; 14: 1163-1170
61 Reil JC, Böhm M. The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol 2007; 96: 585-592
62 Reil JC, Custodis F, Swedberg K et al. Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 2011; 100: 11-19
63 Reil JC, Robertson M, Ford I et al. Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. Eur J Heart Fail 2013; 15: 1044-1052
64 Reil JC, Tardif JC, Ford I et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol 2013; 62: 1977-1985
65 Schmidt H, Müller-Werdan U, Hoffmann T et al. Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups. Crit Care Med 2005; 33: 1994-2002
66 Simon L, Ghaleh B, Puybasset L et al. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995; 275: 659-666
67 Swedberg K, Komajda M, Böhm M et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 2012; 59: 1938-1945
68 Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885
69 Tardif JC, O'Meara E, Komajda M et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 2011; 32: 2507-2515
70 Task Force M. Montalescot G, Sechtem U et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003
71 Tavazzi L, Swedberg K, Komajda M et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. Eur J Heart Fail 2013; 15: 1296-1303
72 Tavazzi L, Swedberg K, Komajda M et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: An efficacy and safety analysis of SHIFT study. Int J Cardiol 2013; 170: 182-188
73 Tverdal A, Hjellvik V, Selmer R. Heart rate and mortality from cardiovascular causes: a 12 year follow-up study of 379,843 men and women aged 40-45 years. Eur Heart J 2008; 29: 2772-2781
74 Umana E, Solares CA, Alpert MA. Tachycardia-induced cardiomyopathy. Am J Med 2003; 114: 51-55
75 Zuanetti G, Hernandes-Bernal F, Rossi A et al. Relevance of heart rate as a prognostic factor in myocardial infarction: the GISSI experience. Eur Heart J 1999; 1 (Suppl. H): H52-H57
76 Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012; 33: 1635-1701